NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA) a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its Cogenics® division has entered into a Scientific Research & Development Agreement with H. Lundbeck A/S to support its ongoing clinical studies with genotyping solutions on a global basis. Lundbeck is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.
